KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Accumulated Expenses (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Accumulated Expenses for 16 consecutive years, with $12.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 3.83% to $12.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.0 million, a 3.83% decrease, with the full-year FY2025 number at $12.0 million, down 3.83% from a year prior.
  • Accumulated Expenses was $12.0 million for Q4 2025 at Biolife Solutions, up from $10.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $12.5 million in Q4 2024 to a low of $350000.0 in Q4 2023.
  • A 5-year average of $7.9 million and a median of $8.2 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: plummeted 96.42% in 2023, then soared 3457.43% in 2024.
  • Biolife Solutions' Accumulated Expenses stood at $1.7 million in 2021, then soared by 490.7% to $9.8 million in 2022, then tumbled by 96.42% to $350000.0 in 2023, then skyrocketed by 3457.43% to $12.5 million in 2024, then decreased by 3.83% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Accumulated Expenses are $12.0 million (Q4 2025), $10.9 million (Q3 2025), and $9.3 million (Q2 2025).